...
首页> 外文期刊>Journal of biomedicine & biotechnology >The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
【24h】

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects

机译:延缓释放氟伐他汀和立即释放氟伐他汀在中国健康受试者中药代动力学和药效动力学的差异

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The aim of this study was to evaluate the difference in pharmacokinetics and pharmacodynamics between extended-release (ER) fluvastatin tablet and its immediate-release (IR) capsule in Chinese healthy subjects. This was an open-label, single/multiple-dose, two-period, two-treatment, crossover, randomized trial with a minimum washout period of 7 days. Twenty healthy male adult subjects were given fluvastatin ER tablet 80 mg QD by oral administration or fluvastatin IR capsule 40 mg BID for seven days. Blood samples were collected up to 24 hours after dosing on day 1 and day 7. Serum concentrations of fluvastatin were determined by LC-MS/MS. For fluvastatin ER tablet 80 mg QD, C_(max) was 61.0 +- 39.0 and 63.9 +- 29.7 ng/mL, and AUC_(0-24h) was 242 +-156 and 253 +- 91.1 ng-h/mL on day 1 and 7, respectively. For fluvastatin IR capsule 40 mg BID, C_(max) was 283 +- 271 and 382 +- 255 ng/mL, and AUC_(0-24h) was 720 +- 776 and 917 +- 994 ng-h/mL on day 1 and day 7, respectively. The relative bioavailability of fluvastatin ER tablet 80 mg QD to fluvastatin IR capsule 40 mg BID is (45.3 +- 23.9)% and (43.3 +- 24.1)% on day 1 and day 7, respectively. T_(max) for fluvastatin ER tablet was 2.50 and 2.60 h and for capsule was 0.78 and 0.88 h on day 1 and day 7, respectively. In the first period, compared to baseline, cholesterol decreased 15.3% in fluvastatin ER tablet 80 mg QD and 16.9% in fluvastatin IR capsule 40 mg BID. Triglyceride decreased 3.7% in fluvastatin ER tablet 80 mg QD and 19.1% in fluvastatin IR capsule 40 mg BID. The difference has no statistical significance at P > 0.05 in reduction percent of cholesterol and triglyceride between the two groups. No adverse events were recorded. The results indicated that C_(max) of fluvastatin ER tablet is reduced and T_(max) is prolonged compared with IR capsule. There is no accumulation for ER formulation after multiple doses.
机译:这项研究的目的是评估在中国健康受试者中,缓释(ER)氟伐他汀片与其速释(IR)胶囊之间的药代动力学和药效学差异。这是一项开放标签,单次/多次,两次,两次治疗,交叉,随机试验,洗脱期最少为7天。二十名健康的男性成年受试者通过口服给予氟伐他汀ER片剂80毫克QD或氟伐他汀IR胶囊40毫克BID,持续7天。在第1天和第7天服药后24小时内收集血样。通过LC-MS / MS测定氟伐他汀的血清浓度。对于氟伐他汀ER片剂80 mg QD,当日C_(max)为61.0±-39.0和63.9±-29.7 ng / mL,而AUC_(0-24h)为242 + -156和253±91.1 ng-h / mL 1和7。对于氟伐他汀IR胶囊40 mg BID,当日C_(max)为283 +-271和382 +-255 ng / mL,而AUC_(0-24h)为720 +-776和917 +-994 ng-h / mL第1天和第7天。在第1天和第7天,氟伐他汀ER片剂80 mg QD与氟伐他汀IR胶囊40 mg BID的相对生物利用度分别为(45.3±23.9)%和(43.3±24.1)%。在第1天和第7天,氟伐他汀ER片剂的T_(max)分别为2.50和2.60 h,胶囊的T_(max)为0.78和0.88 h。在第一阶段,与基线相比,氟伐他汀ER片剂80 mg QD的胆固醇降低了15.3%,氟伐他汀IR胶囊40 mg BID的胆固醇降低了16.9%。氟伐他汀ER片剂80 mg QD中的甘油三酯降低了3.7%,氟伐他汀IR胶囊40 mg BID中的甘油三酯降低了19.1%。两组之间胆固醇和甘油三酯的减少百分比在P> 0.05时,差异无统计学意义。没有不良事件的记录。结果表明,与IR胶囊相比,氟伐他汀ER片的C_(max)降低,T_(max)延长。多次给药后,ER制剂没有积聚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号